FDA takes major step to ease access to CAR-T therapy
The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ post-treatment movement.
The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ post-treatment movement.
